España F, Martínez M, Sánchez-Cuenca J, Vera C D, Estellés A, Jiménez-Cruz J F
Research Center, La Fe University Hospital, Valencia, Spain.
Eur Urol. 1996;30(4):512-8. doi: 10.1159/000474226.
To improve the specificity and sensitivity of the prostate-specific-antigen (PSA) assay for the distinction between prostate cancer and benign prostate hyperplasia (BPH).
Two sensitive immunoassays, one that measures free PSA and PSA complexed to alpha 1-antichymotrypsin (alpha 1-ACT) with the same efficiency (PSAag assay) and another that specifically measures the complex between PSA and alpha 1-ACT, have been designed to measure the PSA forms in the plasma of 84 patients with prostate disease and in the seminal plasma from 60 healthy individuals.
The proportion of plasma PSA in complex with alpha 1-ACT was significantly higher in the 34 patients with prostate cancer (89 +/- 12%, mean +/- SD; median, 91%) than in the 50 patients with BPH (71 +/- 12%; 73%) and did not correlate with the total amount of PSA. Normal seminal plasma (n = 60) had 2.1 +/- 0.6 mg/ml PSA, 175 +/- 62 microns/ml alpha 1-ACT and 9.6 +/- 3.4 micrograms/ml PSA: alpha 1-ACT complex.
These results confirm that PSA: alpha 1-ACT may be a good marker for a differential diagnosis of carcinoma of the prostate and BPH.
提高前列腺特异性抗原（PSA）检测在区分前列腺癌和良性前列腺增生（BPH）方面的特异性和敏感性。
设计了两种灵敏的免疫测定法，一种以相同效率测量游离PSA和与α1-抗糜蛋白酶（α1-ACT）结合的PSA（PSAag测定法），另一种专门测量PSA与α1-ACT之间的复合物，用于检测84例前列腺疾病患者血浆及60例健康个体精浆中的PSA形式。
34例前列腺癌患者血浆中与α1-ACT结合的PSA比例（89±12%，平均值±标准差；中位数为91%）显著高于50例BPH患者（71±12%；73%），且与总PSA量无关。正常精浆（n = 60）中PSA含量为2.1±0.6mg/ml，α1-ACT含量为175±62μg/ml，PSA:α1-ACT复合物含量为9.6±3.4μg/ml。
这些结果证实PSA:α1-ACT可能是前列腺癌和BPH鉴别诊断的良好标志物。
